Cassava Sciences Inc. (SAVA)
2.75
0.14 (5.36%)
At close: Jan 15, 2025, 10:39 AM
Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences Inc.
| Country | United States |
| IPO Date | Jul 14, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Richard Jon Barry |
Contact Details
Address: 7801 North Capital of Texas Highway Austin, Texas United States | |
| Website | https://www.cassavasciences.com |
Stock Details
| Ticker Symbol | SAVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001069530 |
| CUSIP Number | 14817C107 |
| ISIN Number | US14817C1071 |
| Employer ID | 91-1911336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Jon Barry | Chief Executive Officer, President & Director |
| Eric J. Schoen | Chief Financial Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Dr. James W. Kupiec M.D. | Chief Medical Officer |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Freda Nassif | Chief Commercial Officer |
| Jaren Landen | Chief Clinical Development Officer |
| Michael Zamloot | Senior Vice President of Technical Operations |
| R. Christopher Cook J.D. | Senior Vice President, Company Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 8-K | Current Report |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 26, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 3 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 3 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |